Alzheimer patients
-
Practical questions put forward by clinicians in the past have been researched and settled in the thesis. The AD diagnosis is completely based on clinics and the implementation of clinical tests for the diagnosis work depends on assessors’ subjectivity. Therefore, the development of MRI techniques shall help clinicians make diagnosis more quickly and objectively.
27p closefriend09 16-11-2021 31 4 Download
-
Theb-amyloid peptide (Ab) is a major component of toxic amyloid plaques found in the brains of patients with Alzheimer’s disease.Abis liberated by sequential cleavage of amyloid precursor protein (APP) byb-andc-secre-tases.The level of Abdepends directly on the hydrolytic activity ofb-secretase.Therefore, b-secretase is an excel-lent target for drug design.An approach based on RNA-cleaving ribozymes was developed to control expression ofb-secretase.
9p tumor12 20-04-2013 38 4 Download
-
Recently, a novel plaque-associated protein, collagenous Alzheimer amy-loid plaque component (CLAC), was identified in brains from patients with Alzheimer’s disease. CLAC is derived from a type II transmembrane colla-gen precursor protein, termed CLAC-P (collagen XXV). The biological function and the contribution of CLAC to the pathogenesis of Alzheimer’s disease and plaque formation are unknown.
0p awards 06-04-2013 28 2 Download
-
Beta-amyloid (1–40) (Abeta), the main component of senile plaques seen in the brains of Alzheimer’s disease patients, was found to be toxic both as fibrils and smaller soluble globular aggregates. The hydrolytic properties of Abeta, a new biochemical activity described previously [Brzyska M, Bacia A & Elbaum D (2001)Eur J Biochem268, 3443–3454], may contribute to its overall toxicity.
14p inspiron33 23-03-2013 37 4 Download
-
At least two different isoforms ofRCAN1mRNA are expressed in neuro-nal cells in normal human brain. AlthoughRCAN1mRNA is elevated in brain regions affected by Alzheimer’s disease, it is not known whether the disease affects neuronal RCAN1, or if other cell types (e.g. astrocytes or microglia) are affected.
10p galaxyss3 21-03-2013 23 3 Download
-
The amyloidbpeptide (Ab) with 39–42 residues is the major component of amyloid plaques found in brains of Alzheimer’s disease patients, and solu-ble oligomeric peptide aggregates mediate toxic effects on neurons. The Ab aggregation involves a conformational change of the peptide structure to b-sheet.
9p vinaphone15 28-02-2013 45 3 Download
-
Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Sigma-1 receptor agonist fluvoxamine for delirium in patients with Alzheimer’s disease...
3p thulanh11 10-10-2011 41 5 Download
-
Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Current pharmacologic options for patients with Alzheimer's disease...
14p thulanh10 09-10-2011 46 5 Download